Tirzepatide How It Works: Two Hormones, One Molecule

If you want to understand tirzepatide how it works, the GLP-1 story you may already know is only half the answer. Most people first heard about this class of drugs through Ozempic or Wegovy, which target a single incretin hormone. Tirzepatide, the active ingredient in Mounjaro, goes after a second one as well. That extra target changes the picture more than it first appears.

Why a second hormone changes the conversation

Incretins are hormones your gut releases after you eat. They tell the pancreas to release insulin when blood sugar rises, and they slow down how quickly food leaves the stomach. GLP-1 is the best known of them. GIP, short for glucose-dependent insulinotropic polypeptide, is the other major incretin, and it has been studied for decades.

So what does adding GIP activity actually change? That's the question worth asking. The answer is more interesting than a simple "more is better" story, and parts of it are still being worked out. The FDA approved Mounjaro for type 2 diabetes in May 2022, and the label describes its mechanism as activation of both GIP and GLP-1 receptors.

One molecule, two receptor targets

Tirzepatide is a synthetic peptide built from 39 amino acids. A fatty acid chain, specifically a C20 fatty diacid, is attached to the molecule. That chain binds to albumin, a protein already circulating in your blood. Because the drug hitches a ride on albumin, it stays in the bloodstream much longer than it otherwise would. The approximate half-life is about 5 days, which is why the drug is taken once a week.

The term "dual agonist" can sound like there are two separate drugs packed inside one injection. There aren't. It's a single molecule that switches on two receptor systems at the same time. It doesn't hit both receptors with identical strength, though, and that difference in relative activity is part of what makes its profile distinct from a GLP-1-only drug.

What GIP does that GLP-1 doesn't

GIP receptors show up in several places, and one of the most discussed is adipose tissue, or body fat. Researchers think GIP signaling may influence how fat cells store and handle energy. Data from laboratory and animal work suggest this effect is real, but how much it contributes to weight change in people is still being studied.

In the pancreas, GIP also stimulates insulin release in a glucose-dependent way. That means it works more strongly when blood sugar is high and fades as sugar falls. GLP-1 does something similar in principle, so the two hormones share a basic logic here.

The glucagon question is where things get messy. Glucagon is the hormone that raises blood sugar by telling the liver to release stored glucose. Some studies have raised the possibility that GIP could affect glucagon release, and the findings have been debated. Scientists don't yet agree on what that means for the body as a whole, so it's fair to treat this as an open question.

How the signals reach appetite, digestion, and blood sugar

Both receptor systems send signals to the brain, particularly to regions of the hypothalamus that help regulate hunger and fullness. The exact pathways are complex, and researchers are still mapping which signals matter most for which effects.

Tirzepatide also slows gastric emptying, which is the rate at which food leaves the stomach. For some people, this can make meals feel more filling and last longer. The effect varies a lot from person to person, so it doesn't work the same way for everyone.

The glucose-dependent insulin response matters for safety too. Because insulin release rises mainly when glucose is high, the risk of low blood sugar is generally lower when the drug is used without sulfonylureas or insulin. Those other medicines can push blood sugar down on their own, which is why the combination needs closer monitoring.

It's also hard to pull the nervous system effects apart from the gut effects. The brain and the digestive tract talk to each other constantly, so a signal that starts in one often shows up in the other. Any clean separation you see in a diagram is a simplification.

Tirzepatide and semaglutide compared at the mechanism level

Comparing receptor targets is useful for understanding the science, but it doesn't tell you which drug works better. Semaglutide targets GLP-1 only, while tirzepatide targets both GIP and GLP-1. That's the core mechanistic difference, and it is the reason people keep asking how the two compare.

A head-to-head trial called SURMOUNT-5 compared tirzepatide directly with semaglutide. If you want to know how those results were measured, read the design, the endpoints, and the population in the original publication rather than relying on summaries. Differences in receptor profile don't automatically predict who will respond better or who will have more side effects. Biology is rarely that tidy.

What the mechanism explains, and what it doesn't

Knowing how a drug works is not the same as knowing what it will do for you. Understanding the GIP and GLP-1 pathways can help explain why the drug behaves the way it does, but it can't guarantee a result for any individual. Weight outcomes vary widely, and the same medicine can help one person a lot and another person very little.

Mounjaro is a prescription medicine, and the decision to use it belongs with a clinician who knows your health history. The FDA label includes a boxed warning about the risk of thyroid C-cell tumors seen in rodent studies. The drug is not recommended for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Read the full prescribing information before starting, and talk through your own risk factors with your prescriber. For ongoing coverage of these medicines, check out our running coverage of GLP-1 drugs, which follows new data as it comes out.

Closing and next steps for readers

In short, tirzepatide activates two incretin receptors instead of one. GIP and GLP-1 each contribute to insulin release, the gut, and signals to the brain, and the way they combine may explain part of the drug's profile. Much of the detail is still under study, especially the role of GIP in fat tissue and glucagon.

If you're considering this medicine, bring specific questions to your prescriber. Ask how the dose will change over time. The FDA label lists a starting dose of 2.5 mg once weekly, with increases in set steps, so ask what the titration schedule looks like for you and when a dose change would happen. Ask which side effects to watch for and when to call. Ask how your blood sugar or weight will be checked. If you want to prepare, the OzemNews archive has past pieces that cover many of these topics in more depth.

Finally, if you want to keep learning, browse the other posts on this blog. Our reporting on GLP-1 news covers new trial results, label updates, and practical questions readers raise, so it's a good next step once you've got your questions lined up.

FAQ

Is tirzepatide the same as semaglutide?

No. They are different molecules. Both work through the GLP-1 pathway, but tirzepatide also activates GIP receptors, while semaglutide targets GLP-1 only.

Does Mounjaro work only by reducing appetite?

Probably not. Researchers think several pathways contribute, including brain signaling, slower gastric emptying, and effects on insulin and fat tissue. How much each one matters is still being studied.

Why is tirzepatide taken once a week?

The molecule is bound to albumin, which keeps it in the bloodstream for a long time. Its approximate half-life of about 5 days supports a once-weekly schedule.

Who should not use Mounjaro?

The label says the drug is not recommended for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Your prescriber can review your history and tell you whether it fits your situation.

Can understanding the mechanism predict my results?

Not for any one person. The mechanism helps explain how the drug can help, but outcomes vary, and a clinician should guide the decision.

Sources

• Mounjaro (tirzepatide) Prescribing Information, U.S. Food and Drug Administration
• Once-Weekly Tirzepatide for Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2), The Lancet, 2023
• Tirzepatide versus Semaglutide for Obesity (SURMOUNT-5), New England Journal of Medicine, 2025